Bone Biologics (BBLGW) EBIT (2010 - 2026)

Bone Biologics (BBLGW) has reported EBIT for 17 consecutive years, with -$808106.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBIT fell 8.02% year-over-year to -$808106.0 in Q2 2026; TTM through Jun 2026 was -$3.0 million, a 30.0% increase from a year earlier, with the FY2025 full-year figure at -$3.2 million, up 23.33% from the prior year.
• EBIT was -$808106.0 for Q2 2026 at Bone Biologics, down from -$733105.0 in the prior quarter.
• Over five years, EBIT peaked at -$469304.0 in Q2 2022 and troughed at -$3.1 million in Q1 2023.
• A 5-year average of -$1.3 million and a median of -$951021.0 in 2024 frame the typical range for EBIT.
• Across the five-year window, EBIT sank 547.74% in 2023 and surged 73.37% in 2024, its largest moves.
• Over 5 years, EBIT stood at -$1.3 million in 2022, then climbed by 9.87% to -$1.2 million in 2023, then tumbled by 34.05% to -$1.6 million in 2024, then soared by 52.85% to -$733105.0 in 2025, then dropped by 10.23% to -$808106.0 in 2026.
• The last three EBIT figures came in at -$808106.0 (Q2 2026), -$733105.0 (Q4 2025), and -$715274.0 (Q3 2025), per Business Quant data.